학술논문
Neurological adverse events post allogeneic hematopoietic cell transplantation: major determinants of morbidity and mortality.
Document Type
Article
Author
Sakellari, Ioanna; Gavriilaki, Eleni; Papagiannopoulos, Sotirios; Gavriilaki, Maria; Batsis, Ioannis; Mallouri, Despina; Vardi, Anna; Constantinou, Varnavas; Masmanidou, Marianna; Yannaki, Evangelia; Smias, Christos; Geroukis, Triantafyllos; Kazis, Dimitrios; Kimiskidis, Vasileios; Anagnostopoulos, Achilles
Source
Subject
*CELL transplantation
*ADVERSE health care events
*DISEASES
*GRAFT versus host disease
*CENTRAL nervous system
*
*
*
*
Language
ISSN
0340-5354
Abstract
Background: Despite advances in the field, diagnosis and management of the wide spectrum of neurological events post allogeneic hematopoietic cell transplantation (alloHCT) remain challenging. Therefore, we investigated their incidence, diagnosis, management and long-term prognosis in alloHCT recipients. Methods: We retrospectively recorded data from consecutive alloHCT recipients with or without neurological complications in our center. Results: Among 758 alloHCT recipients, 127 (16.8%) presented with neurological complications. Complications developed in central nervous system (89.7%) during the late post-transplant period. Neurological adverse events included a wide spectrum of infectious and non-infectious etiologies. With a median follow-up of 11.4 months, incidence of chronic graft-versus-host disease (GVHD) was 52.8%, relapse mortality 48.6%, transplant-related mortality 39.1% and 5-year overall survival (OS) 25.8% in patients with neurological complications. Timing of appearance of neurological complications, early or late, was associated only with acute and chronic graft-versus-host-disease/GVHD. Independent pre-transplant risk factors of neurological complications in the multivariate model were unrelated or alternative donors, ALL diagnosis and non-myeloablative conditioning. In multivariate analysis of post-alloHCT events, favorable OS was independently associated with resolution of neurological syndromes, absence of chronic GVHD and sibling transplantation. In our cohort, 10-year OS was significantly lower in patients with neurological complications and independently associated with acute and chronic GVHD, relapse, fungal and bacterial infections and neurological complications. Conclusions: Our large study with long-term follow-up highlights the wide spectrum of neurological complications in alloHCT. Accurate recognition is required for adequate management, a major determinant of survival. Thus, long-term increased awareness and collaboration between expert physicians is warranted. [ABSTRACT FROM AUTHOR]